Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia

Blood

Volumn 120, Issue 10, 2012, Pages 2127-2132

  Aslam, Rukhsana ^a,b,c   Hu, Yu ^a,b   Gebremeskel, Simon ^a,b   Segel, George B ^d   Speck, Edwin R ^a,b,c   Guo, Li ^a,b   Kim, Michael ^a,b   Ni, Heyu ^a,b,c,e   Freedman, John ^a,b,e   Semple, John W ^a,b,c,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD61 ANTIGEN; HUMAN IMMUNOGLOBULIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CD4+ CD25+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DISEASE MODEL; ENGRAFTMENT; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCID MOUSE; SPLEEN; SPLEEN CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYMUS;

EID: 84866177904     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-413526     Document Type: Article

References (47)

1. Semple JW, Provan D, Garvey MB, Freedman J. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol. 2010;17(6):590-595.
2. Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99(1):4-13.
3. Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
4. Semple JW. Infections, antigen-presenting cells, T cells, and immune tolerance: their role in the pathogenesis of immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23(6):1177-1192.
5. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009;23(6):1163-1175.
6. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887-895.
7. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-1369.
8. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951;38(1):1-10.
9. Olsson B, Andersson P, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thromocytopenic purpura. Nat Med. 2003;9(9):1123-1124.
10. Zhang F, Chu K, Wang L, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006;76(5):427-431.
11. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010;115(6):1247-1253.
12. Liu B, Zhoa H, Poon MC, et al. Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Hematol. 2006;78(2):139-143.
13. Fahim NMA, Monir E. Functional role of CD4+CD25+ regulatory T cells and transforming growth factor-beta1 in childhood immune thrombocytopenic purpura. Egypt J Immunol. 2006;13(1):173-187.
14. Sakakura M, Wada H, Tawara I, et al. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007;120(2):187-193.
15. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Hematol. 2007;79(4):310-316.
16. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112(4):1325-1328.
17. Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood. 2008;112(4):1078-1084.
18. Stasi R, Cooper N, DelPoeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112(4):1147-1150.
19. Zhang X-L, Peng J, Sun JZ, et al. De novo induction of platelet-specific CD4+CD25+ regulatory T cells from CD4+CD25- cells in patients with idiopathic thrombocytopenic purpura. Blood. 2009;113(11):2568-2577.
20. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639-4645.
21. Abudureheman A, Yassen H, Fang Z, et al. Expression of CD4+ CD25+ regulatory T cells and TGF-s1 in patient with idiopathic thrombocytopenic purpura. Xibao Yu Fenzi Mianyixue Zazhi. 2010;26(9):895-897.
22. Park SH, Kim JY, Kim SK, et al. Regulatory T-cells in systemic lupus erythematosus-associated thrombocytopenia: a comparison with idiopathic thrombocytopenic purpura. Lupus. 2010;19(7):888-889.
23. Chang DY, Ouyang J, Zhou RF, et al. Profiles of different subsets of CD(4)(+) T cells in chronic idiopathic thrombocytopenic purpura. Chin J Int Med. 2010;49(3):213-216.
24. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol. 2010;47(2):170-179.
25. Zhao H, Du W, Wang D, et al. The expression of IFN-gamma, IL-4, Foxp3 and perforin genes are not correlated with DNA methylation status in patients with immune thrombocytopenic purpura. Platelets. 2010;21(2):137-143.
26. Wang C, Fu JL, Lu YY, et al. Levels of regulatory T cells in peripheral blood of children with idiopathic thrombocytopenic purpura. Zhongguo Dangdai Erke Zazhi. 2011;13(4):282-284.
27. Li N, Mou W, Lu G, et al. Low-dose rituximab combined with short-term glucocorticoids upregulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93(1):91-98.
28. Aboul-Fotoh Lei M, Abdel Raheem MM, El-Deen MA, Osman AM. Role of CD4+CD25+ T cells in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2011;33(2):81-85.
29. Audia S, Samson M, Guy J, et al. Immunological effects of rituximab on the human spleen in immune thrombocytopenia. Blood. 2011;118(16): 4394-4400.
30. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27(1):20-21.
31. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001;27(1):68-73.
32. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490-500.
33. David R. Regulatory T cells: fine-tuning Treg cells. Nat Rev Immunol. 2009;9:226-227.
34. Semple JW, Speck ER, Cosgrave D, Lazarus AH, Blanchette V, Freedman J. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood. 1999;93(2):713-720.
35. Watanabe M, Aiso S, Hibi T, et al. Alteration of T cell maturation and proliferation in the mouse thymus induced by serum factors from patients with ulcerative colitis. Clin Exp Immunol. 1987;68(3):596-597.
36. Verinaud L, Da Cruz-Hofling MA, Sakurada JK, et al. Immunodepression induced by Trypanosoma cruzi and mouse hepatitis virus type 3 is associated with thymus apoptosis. Clin Diagn Lab Immunol. 1998;5(2):186-191.
37. Maddur MS, Othy S, Hedde P, et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010;30(Suppl 1):S4-S8.
38. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol. 2007;179(8):5571-5575.
39. Wang HB, Zhang Y, Wang WZ. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome. J Neuroimmunol. 2007;192(1):206-214.
40. Ephrem A, Chamat S, Miguel C, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111(92):715-722.
41. Furuno K, Yugr T, Kusuhara K, et al. CD25+CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatr. 2004;145(3):385-390.
42. Olivito B, Taddio A, Simonini G, et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol. 2010;28(1 Suppl 57):93-7.
43. Tha-In T, Metselaar HJ, Bushell AR, Kwekkeboom J, Wood KJ. Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells. Transplantation. 2010;89(12):1446-1455.
44. Pavlovic S, Zdravkovic N, Dimitrov JD, et al. Intravenous immunoglobulins exposed to heme (heme IVIgG) are more efficient than IVIG in attenuating autoimmune diabetes. Clin Immunol. 2011;138(2):162-171.
45. Riecke K, Nogueira AC, Alexi-Meskishvili V, Stahlmann R. Cross-reactivity of antibodies on thymic epithelial cells from humans and marmosets by flow-cytometry. J Med Primatol. 2000;29(5):343-349.
46. Merono A, Lucena C, López A, Garrido JJ, Pérez de LL, Llanes D. Immunohistochemical analysis of beta3 integrin (CD61): expression in pig tissues and human tumors. Histol Histopathol. 2002;17(2):347-352.
47. Corbel C, Vaigot P, Salaün J. (alpha)IIb Integrin, a novel marker for hemopoietic progenitor cells. Int J Dev Biol. 2005;49(2):279-284.